ENTA is a screaming buy based on valuation, IMO. ABT-450 is a so-so drug, but the economics of ENTA’s partnership with ABBV (#msg-89280314) almost assure that the share price will rise unless a safety problem derails ABBV’s HCV program (#msg-90408583, #msg-90352754). On top of that, you get the NVS partnership for free.
Market Data 
Markets 
AI
